Metrikler
Yayın
115
Açık Erişim
21
BM Sürdürülebilir Kalkınma Amaçları
Eğitim Bilgileri
1998 - 2001
1998 - 2001Tıpta Yandal Uzmanlık
Hacettepe Üniversitesi, Medikal Onkoloji, Türkiye
1992 - 1997
1992 - 1997Tıpta Uzmanlık
Hacettepe Üniversitesi, İç Hastalıkları, Türkiye
1986 - 1992
1986 - 1992Lisans
Hacettepe Üniversitesi, Tıp, Türkiye
Yabancı Diller
C1 İleri
C1 İleriFransızca
C2 Ustalık
C2 Ustalıkİngilizce
Araştırma Alanları
Tıp
Sağlık Bilimleri
Dahili Tıp Bilimleri
İç Hastalıkları
Onkoloji
Akademik Faaliyetlere Dayalı Araştırma Alanları
Avesis Araştırma Alanları
WoS Araştırma Alanları
Scopus Araştırma Alanları
Akademik Ünvanlar / Görevler
2016 - Devam Ediyor
2016 - Devam EdiyorProf. Dr.
Hacettepe Üniversitesi, Kanser Enstitüsü, Prevantif Ve Onkoloji Anabilim Dalı
2006 - 2016
2006 - 2016Doç. Dr.
Hacettepe Üniversitesi, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü
2005 - 2006
2005 - 2006Yrd. Doç. Dr.
Hacettepe Üniversitesi, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü
2001 - 2005
2001 - 2005Öğretim Görevlisi Dr.
Hacettepe Üniversitesi, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü
Yönetimsel Görevler
2019 - Devam Ediyor
2019 - Devam EdiyorEnstitü Müdür Yardımcısı
Hacettepe Üniversitesi, Kanser Enstitüsü
2017 - Devam Ediyor
2017 - Devam EdiyorMerkez Müdür Yardımcısı
Hacettepe Üniversitesi, Hacettepe Üniversitesi Klinik Araştırmalar Uygulama Ve Araştırma Merkezi (Hükam)
Akademi Dışı Deneyim
2016 - Devam Ediyor
2016 - Devam EdiyorProfesör
Hacettepe Üniversitesi, Profesör
2006 - 2016
2006 - 2016Doçent
Hacettepe Üniversitesi, Doçent
2005 - 2006
2005 - 2006Yardımcı Doçent
Hacettepe Üniversitesi, Yardımcı Doçent
2001 - 2005
2001 - 2005Öğretim Görevlisi
Hacettepe Üniversitesi, Öğretim Görevlisi
1997 - 2001
1997 - 2001Uzman Araştırma Görevlisi
Hacettepe Üniversitesi, Uzman Araştırma Görevlisi
1992 - 1997
1992 - 1997Araştırma Görevlisi
Hacettepe Üniversitesi, Araştırma Görevlisi
Makaleler
Tümü (97)
SCI-E, SSCI, AHCI (90)
SCI-E, SSCI, AHCI, ESCI (95)
ESCI (4)
Scopus (92)
TRDizin (12)
2025
20251. The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancer
YILMAZ F., Yaşar S., Tatar O. D., Yildirim H. c., Guven D. C., TABAN H., et al.
Acta Medica
, cilt.56, sa.3, ss.186-198, 2025 (TRDizin)
2025
20252. Early Changes in Volumetric Body Composition Parameters Predict Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy
AKTEPE O. H., ERDEMİR A. G., Yildirim E. C., Demirciler E., ULAŞLI T., GÜVEN D. C., et al.
JOURNAL OF CLINICAL MEDICINE
, sa.9, 2025 (SCI-Expanded, Scopus)
2025
20253. The association between blood sodium levels and survival in patients treated with immune checkpoint inhibitors
ŞAHİN T. K., GÜVEN D. C., Durukan M., KAVGACI G., KAYGUSUZ Y., ARIK Z., et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
, sa.4, ss.129-137, 2025 (SCI-Expanded)
2025
20254. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study
Topal A., Akdag G., Yildirim S., Kinikoglu O., Isik D., Yildirim G., et al.
MEDICINA-LITHUANIA
, sa.3, 2025 (SCI-Expanded, Scopus)
2025
20255. Comparative Analysis of Prognostic Potential of Pretreatment Blood-Based Biomarkers in Metastatic Bladder Cancer: Modified Glasgow Prognostic Score
KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., Koc I., Tatar O. D., et al.
JOURNAL OF CLINICAL MEDICINE
, sa.6, 2025 (SCI-Expanded, Scopus)
2025
20256. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program (EAP).
Tural D., Ozkan O., YASLIKAYA Ş., TATLI A. M., Akdag G., Demir H., et al.
JOURNAL OF CLINICAL ONCOLOGY
, sa.5_SUPPL, 2025 (SCI-Expanded, Scopus)
2025
20257. The association between HALP score and survival in patients treated with immune checkpoint inhibitors
ŞAHİN T. K., GÜVEN D. C., Durukan M., BAŞ O., KAYGUSUZ Y., ARIK Z., et al.
EXPERT REVIEW OF ANTICANCER THERAPY
, sa.1, ss.81-89, 2025 (SCI-Expanded)
2024
20248. Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer
YILMAZ F., YAŞAR S., Tatar O. D., Yildirim H. C., Guven D. C., AKYILDIZ A., et al.
BMC CANCER
, cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)
2024
20249. Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with Immunotherapy
Degerli E., Arslan C., Selcukbiricik F., Olmez O. F., Erdem D., Hamdard J., et al.
MEDICINA-LITHUANIA
, cilt.60, sa.12, 2024 (SCI-Expanded, Scopus)
2024
202410. Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder Cancer
Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Akar E., ERMAN M., et al.
CLINICAL GENITOURINARY CANCER
, cilt.22, sa.6, 2024 (SCI-Expanded, Scopus)
2024
202411. Efficacy of Systemic Treatments in Patients With Metastatic Lung Invasive Mucinous Adenocarcinoma
Demir T., Araz M., Moloney C., Hendem E., Kocak M. Z., ERMAN M., et al.
CLINICAL LUNG CANCER
, sa.7, 2024 (SCI-Expanded, Scopus)
2024
202412. Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors
Tural D., Arslan C., Selcukbiricik F., ÖLMEZ Ö. F., ERMAN M., ÜRÜN Y., et al.
CLINICAL GENITOURINARY CANCER
, cilt.22, sa.5, 2024 (SCI-Expanded, Scopus)
2024
202413. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma
Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Guzel H. G., et al.
JOURNAL OF CHEMOTHERAPY
, 2024 (SCI-Expanded, Scopus)
2024
202414. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
Lara Jr P. N., Villanueva L., Ibanez C., ERMAN M., Lee J. L., Heinrich D., et al.
BMC CANCER
, cilt.23, sa.SUPPL 1, 2024 (SCI-Expanded, Scopus)
2024
202415. Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors
KAVGACI G., GÜVEN D. C., KAYGUSUZ Y., KARACA E., DİZDAR Ö., Kilickap S., et al.
SUPPORTIVE CARE IN CANCER
, cilt.32, sa.7, 2024 (SCI-Expanded, Scopus)
2024
202416. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)
YAŞAR H. A., AKTAŞ B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., et al.
Clinical Genitourinary Cancer
, cilt.22, sa.3, 2024 (SCI-Expanded, Scopus)
2024
202417. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy
KILIÇKAP S., Ozturk A., Karadurmus N., KORKMAZ T., YUMUK P. F., ÇİÇİN İ., et al.
MEDICINE
, cilt.103, sa.21, 2024 (SCI-Expanded, Scopus)
2024
202418. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study
Guven D. C., Aykan M. B., MUĞLU H., BAYRAM E., Helvaci K., DURSUN B., et al.
Cancer Medicine
, cilt.13, sa.1, 2024 (SCI-Expanded, Scopus)
2023
202319. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab
YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., et al.
Journal of Immunotherapy and Precision Oncology
, cilt.6, sa.4, ss.170-176, 2023 (Scopus)
2023
202320. Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?
GÜNER G., AKTAŞ B. Y., Başal F. B., DEMİRKAZIK A., Gürsoy P., Demirci U., et al.
Journal of Cancer Research and Clinical Oncology
, cilt.149, sa.14, ss.13271-13277, 2023 (SCI-Expanded, Scopus)
2023
202321. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study
GÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
, cilt.149, sa.7, ss.3599-3606, 2023 (SCI-Expanded, Scopus)
2023
202322. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.
Anti-Cancer Drugs
, cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded, Scopus)
2023
202323. Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice
Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Akar E., ERMAN M., et al.
Clinical Genitourinary Cancer
, cilt.21, sa.3, ss.334-341, 2023 (SCI-Expanded, Scopus)
2023
202324. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy
GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.
INTERNATIONAL JOURNAL OF CANCER
, cilt.152, ss.679-685, 2023 (SCI-Expanded, Scopus)
2023
202325. NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
de Castro G., Rizvi N. A., Schmid P., Syrigos K., Martin C., Yamamoto N., et al.
Journal of Thoracic Oncology
, cilt.18, sa.1, ss.106-119, 2023 (SCI-Expanded, Scopus)
2022
202226. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.
JOURNAL OF CLINICAL MEDICINE
, cilt.11, sa.17, 2022 (SCI-Expanded, Scopus)
2022
202227. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy
GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., et al.
JOURNAL OF CLINICAL MEDICINE
, cilt.11, sa.15, 2022 (SCI-Expanded, Scopus)
2022
202228. The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy
GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.28, sa.4, ss.785-793, 2022 (SCI-Expanded, Scopus)
2022
202229. Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.
Guven D. C., Sayegh N., Tripathi N., Erman M., Agarwal N., Swami U.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.40, sa.16, 2022 (SCI-Expanded, Scopus)
2022
2022
30.
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)& nbsp;
Levy B., Barlesi F., Paz-Ares L., Bennouna J., ERMAN M., Felip E., et al.
LUNG CANCER
, cilt.166, ss.107-113, 2022 (SCI-Expanded, Scopus)
2022
202231. Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma
Tural D., Selcukbiricik F., Olmez O. F., Sumbul A. T., ERMAN M., COŞKUN H. Ş., et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
, cilt.27, sa.3, ss.585-591, 2022 (SCI-Expanded, Scopus)
2022
202232. Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma
Ismayilov R., AKTEPE O. H., Sardarova K., LEBLEBİCİ C. B., ERMAN M.
EURASIAN JOURNAL OF MEDICINE
, cilt.54, sa.1, ss.77-79, 2022 (ESCI, Scopus, TRDizin)
2022
202233. Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice.
Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Erman M., Urun Y., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.40, sa.6, 2022 (SCI-Expanded, Scopus)
2022
202234. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, cilt.6, sa.1, ss.59-63, 2022 (ESCI, TRDizin)
2021
202135. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study
GÜVEN D. C., Acar R., Yekeduz E., Bilgetekin I., Baytemur N. K., EROL C., et al.
CURRENT PROBLEMS IN CANCER
, cilt.45, sa.6, 2021 (SCI-Expanded, Scopus)
2021
202136. The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy
AKTEPE O. H., GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇELİKTEN B., Yeter H. H., et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
, cilt.73, sa.10, ss.1957-1963, 2021 (SCI-Expanded, Scopus)
2021
202137. Should Protocols Specific to Histologic Subtypes Be Applied in the Follow-Up of NSCLC?
ARIK Z., ERMAN M.
JOURNAL OF THORACIC ONCOLOGY
, cilt.16, sa.10, 2021 (SCI-Expanded, Scopus)
2021
202138. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy
GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus)
2021
202139. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors
GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.
BIOMARKERS IN MEDICINE
, cilt.15, sa.13, ss.1123-1130, 2021 (SCI-Expanded, Scopus)
2021
202140. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
Blackhall F., Jao K., Greillier L., Cho B. C., Penkov K., Reguart N., et al.
JOURNAL OF THORACIC ONCOLOGY
, cilt.16, sa.9, ss.1547-1558, 2021 (SCI-Expanded, Scopus)
2021
202141. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences
Tural D., Olmez O. F., Sumbul A. T., ARTAÇ M., Ozhan N., Akar E., et al.
EUROPEAN UROLOGY FOCUS
, cilt.7, sa.5, ss.1061-1066, 2021 (SCI-Expanded, Scopus)
2021
202142. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab
Tural D., Olmez O. F., Sumbul A. T., Ozhan N., ÇAKAR B., Kostek O., et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
, cilt.26, ss.1506-1513, 2021 (SCI-Expanded, Scopus)
2021
202143. Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?
Sari S. Y., AKTAŞ B. Y., KERTMEN N., ELMALI A., Kilickap S., Oguz K. K., et al.
CUREUS
, cilt.13, sa.6, 2021 (ESCI)
2021
202144. THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION
, cilt.36, 2021 (SCI-Expanded, Scopus)
2021
202145. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors
GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., et al.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.4, ss.2029-2035, 2021 (SCI-Expanded, Scopus)
2021
202146. Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma
AKTEPE O. H., GÜNER G., GÜVEN D. C., TABAN H., YILDIRIM H. Ç., ŞAHİN T. K., et al.
TURKISH JOURNAL OF UROLOGY
, cilt.47, sa.2, ss.113-119, 2021 (ESCI, Scopus, TRDizin)
2021
202147. Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.
Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.39, sa.6, 2021 (SCI-Expanded, Scopus)
2021
202148. Survival Outcomes of Patients in Advanced Non-Clear Renal Cell Carcinoma Treated with Pazopanib: A Retrospective Single Institution Experience
AKTEPE O. H., ERMAN M.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.31, sa.3, ss.170-177, 2021 (SCI-Expanded, Scopus, TRDizin)
2020
202049. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients
Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., et al.
LUNG CANCER
, cilt.148, ss.48-54, 2020 (SCI-Expanded, Scopus)
2020
202050. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma
BAŞ O., Ozbek A., Guven D., Aktepe O., KILIÇ L., KERTMEN N., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.5, ss.1230-1233, 2020 (SCI-Expanded, Scopus)
2020
202051. Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic
Kucuk E., EKİNCİOĞLU A., ERMAN M., KILIÇKAP S.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.3, ss.595-602, 2020 (SCI-Expanded, Scopus)
2019
201952. Electrophysiologic evaluation of facial nerve functions after oxaliplatin treatment
Yiğit Ö., Kulak Kayıkcı M. E., Temuçin Ç. M., Sarac S., Erman M., Belgin E.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
, cilt.84, sa.3, ss.513-520, 2019 (SCI-Expanded, Scopus)
2019
201953. Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability
KILIÇKAP S., Onder S., DİZDAR Ö., ERMAN M., ÜNER A.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
, cilt.83, sa.6, ss.1195-1196, 2019 (SCI-Expanded, Scopus)
2019
201954. Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol
Levy B., Paz-Ares L., Bennouna J., Felip E., Rodriguez Abreu D., Isla D., et al.
CLINICAL LUNG CANCER
, cilt.20, sa.3, 2019 (SCI-Expanded, Scopus)
2018
201855. Middle East observational study in metastatic soft tissue sarcoma: an epidemiological study on the treatment patterns (MOON)
Memon M. A., Karaca B., Aboelhassan R., Barsoum M., ERMAN M., Basaran M., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
, cilt.144, sa.11, ss.2219-2229, 2018 (SCI-Expanded, Scopus)
2018
201856. Factors associated with quitting action following smoking cessation counseling.
Hayran K. M., Yuce D., Erman M., Dizdar O., Kilickap S., HUSEYIN B.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)
2018
201857. Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung
Levy B. P., Paz-Ares L. G., Bennouna J., Felip E., Abreu D. R., Isla D., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)
2018
201858. Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors
Tecen-Yucel K., Bayraktar-Ekincioglu A., KILIÇKAP S., ERMAN M.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.28, sa.1, ss.53-60, 2018 (SCI-Expanded, Scopus, TRDizin)
2017
201759. BİR SİGARA BIRAKMA POLİKLİNİĞİNDE UYGULANAN PSİKOEĞİTİMSEL SİGARA BIRAKMA POROGRAMININ ETKİNLİĞİ
KAMIŞLI S., YÜCE D., küçükçoban ş., HAYRAN K. M., KILIÇKAP S., ÇELİK İ., et al.
Anadolu Hemşirelik ve Sağlık Bilimleri Dergisi , cilt.20, sa.4, ss.234-242, 2017 (TRDizin)
2016
201660. Survival following laparoscopic adrenalectomy for solitary metastasis of lung cancer
Tonyali S., HABERAL H. B., Yazici S., ERMAN M., KAYNAROĞLU Z. V., BİLEN C. Y.
INTERNATIONAL UROLOGY AND NEPHROLOGY
, cilt.48, sa.11, ss.1803-1809, 2016 (SCI-Expanded, Scopus)
2016
201661. Vaccination perception and attitudes among patients with cancer receiving chemotherapy
AKIN Ş., DİZDAR Ö., Karakas Y., ÖZIŞIK L., Tanriover M. D., Kamisli S., et al.
ANNALS OF ONCOLOGY
, cilt.27, 2016 (SCI-Expanded, Scopus)
2016
201662. Renal cell cancer: overview of the current therapeutic landscape
ERMAN M., Benekli M., Basaran M., BAVBEK S., Buyukberber S., Coskun U., et al.
EXPERT REVIEW OF ANTICANCER THERAPY
, cilt.16, sa.9, ss.955-968, 2016 (SCI-Expanded, Scopus)
2016
201663. Effect of Zoledronic Acid on Rats' Tissue SDF-1 Expression
Arik Z., KILIÇKAP S., AKPULAT U., Nahit Sendur M. A., KOCAEFE Y. Ç., ERMAN M.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.26, sa.4, ss.215-219, 2016 (SCI-Expanded, Scopus, TRDizin)
2016
201664. Vaccination Attitudes Among Patients with Cancer Receiving Chemotherapy
AKIN S., DİZDAR Ö., ÖZIŞIK L., TANRIOVER M., KAMISLI S., ERMAN M., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.26, sa.3, ss.167-172, 2016 (SCI-Expanded, Scopus, TRDizin)
2015
201565. QUALITY OF LIFE DOMAINS ASSOCIATED WITH READMISSION
HAYRAN K. M., YÜCE D., Huseyin B., Esin E., KILIÇKAP S., ERMAN M., et al.
VALUE IN HEALTH
, cilt.18, sa.3, 2015 (SCI-Expanded, SSCI, Scopus)
2015
201566. Nationwide Smoking Cessation Treatment Support Program - Turkey project
ÇELİK İ., YÜCE D., Hayran M., ERMAN M., KILIÇKAP S., BUZĞAN T., et al.
HEALTH POLICY
, cilt.119, sa.1, ss.50-56, 2015 (SCI-Expanded, SSCI, Scopus)
2014
201467. ASSOCIATION OF HEALTH CARE COST WITH QUALITY OF LIFE FOR VARIOUS TYPES OF CANCERS
HAYRAN K. M., YÜCE D., Huseyin B., Esin E., KILIÇKAP S., ERMAN M., et al.
VALUE IN HEALTH
, cilt.17, sa.7, 2014 (SCI-Expanded, SSCI, Scopus)
2014
201468. HEALTH RELATED QUALITY OF LIFE IN CANCER PATIENTS: EVALUATION WITH A SELF-ADMINISTERED IPAD APPLICATION
YÜCE D., HAYRAN K. M., KILIÇKAP S., ERMAN M., ÇELİK İ.
VALUE IN HEALTH
, cilt.17, sa.7, 2014 (SCI-Expanded, SSCI, Scopus)
2013
201369. Aromatase Inhibitors and Safety: Clinical or Statistical Significance?
Esin E., YÜCE D., KILIÇKAP S., ERMAN M.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.31, sa.27, ss.3439, 2013 (SCI-Expanded, Scopus)
2013
201370. Effect of Endocrine Therapy on Quality of Life and Cognitive Functions in Patients with Breast Cancer
KILIÇKAP S., HAYRAN M., ÇAKIR B., ÇİLİNGİROĞLU N., ERMAN M., Buyukdamgaci G., et al.
BREAST CARE
, cilt.8, sa.2, ss.128-132, 2013 (SCI-Expanded, Scopus)
2012
201271. Pituitary Gland Metastasis of Breast Cancer: A Case Report
Ozkan C., ARSLAN Ç., KILIÇ M., ERMAN M., Altundag K.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.22, sa.1, ss.42-45, 2012 (SCI-Expanded, Scopus, TRDizin)
2011
201172. Isolated Bone Metastases in Early Stage Endometrial Adenocarcinoma: A Case Report and Review of the Literature
Kurt M., KILIÇKAP S., AKSOY S., ERMAN M., Gedikoglu G., Turker A.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.21, sa.1, ss.52-56, 2011 (SCI-Expanded, Scopus, TRDizin)
2011
201173. FREQUENCY OF CANCER TYPES IN PATIENTS AGED 65 AND OLDER: RESULTS FROM CANCER REGISTRY DATABASE OF HACETTEPE UNIVERSITY HOSPITALS
Arslan C., KILIÇKAP S., Dede D. S., HAYRAN K. M., ERMAN M., ÇELİK İ., et al.
TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI
, cilt.14, sa.3, ss.187-192, 2011 (SCI-Expanded, SSCI, Scopus, TRDizin)
2008
200874. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma
KILIÇKAP S., Yavuz B., AKSOY S., Sahiner L., DİNÇER M., HARPUTLUOĞLU H., et al.
MEDICAL ONCOLOGY
, cilt.25, sa.4, ss.437-442, 2008 (SCI-Expanded, Scopus)
2008
200875. Platelet size has diagnostic predictive value for bone marrow metastasis in patients with solid tumors
AKSOY S., KILIÇKAP S., Hayran M., HARPUTLUOĞLU H., KOCA E., Dede D. S., et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
, cilt.30, sa.3, ss.214-219, 2008 (SCI-Expanded, Scopus)
2008
200876. Erectile dysfunction in successfully treated lymphoma patients
AKSOY S., HARPUTLUOĞLU H., KILIÇKAP S., DİNÇER M., DİZDAR Ö., AKDOĞAN B., et al.
SUPPORTIVE CARE IN CANCER
, cilt.16, sa.3, ss.291-297, 2008 (SCI-Expanded, Scopus)
2008
200877. A decision-analytic model for early stage breast cancer: Lumpectomy vs mastectomy
Alogan G. B., Elele T., Hayran M., ERMAN M., KILIÇKAP S.
NEOPLASMA
, cilt.55, sa.3, ss.222-228, 2008 (SCI-Expanded, Scopus)
2007
200778. Vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and cyclooxygenase-2 expression in psoriasis
YALÇIN B., Tezel G. G., ARDA N., ERMAN M., ALLI N.
ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY
, cilt.29, sa.6, ss.358-364, 2007 (SCI-Expanded, Scopus)
2007
200779. Molecular mechanisms of signal transduction: Epidermal growth factor receptor family, Vascular endothelial growth factor family, Kit, Platelet-derived growth factor receptor, Ras
Erman M.
JOURNAL OF BUON
, cilt.12, 2007 (SCI-Expanded, Scopus)
2007
200780. Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab
Kalyoncu U., Karadag O., Akdogan A., KISACIK B., Erman M., Erguven S., et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
, cilt.39, sa.5, ss.475-478, 2007 (SCI-Expanded, Scopus)
2007
200781. Thymic epithelial neoplasia - A study of 58 cases
ELKIRAN E. T., Abali H., Aksoy S., Altundag K., Erman M., Kars A., et al.
MEDICAL ONCOLOGY
, cilt.24, sa.2, ss.197-201, 2007 (SCI-Expanded, Scopus)
2006
200682. Expressions of vascular endothelial growth factor and CD34 in oral aphthous lesions of Behcet's disease
YALÇIN B., ARDA N., Tezel G. G., ERMAN M., ALLI N.
ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY
, cilt.28, sa.6, ss.303-306, 2006 (SCI-Expanded, Scopus)
2006
200683. Extensive exfoliative dermatitis induced by chlorambucil
Kilickap S., Kurt M., Aksoy S., Erman M., Turker A.
AMERICAN JOURNAL OF HEMATOLOGY
, cilt.81, sa.11, ss.891-892, 2006 (SCI-Expanded, Scopus)
2006
200684. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient
Aksoy S., Abali H., Kilickap S., Erman M., Kars A.
CLINICAL AND LABORATORY HAEMATOLOGY
, cilt.28, sa.3, ss.211-214, 2006 (SCI-Expanded, Scopus)
2006
200685. Nasopharynx carcinoma complicated with pneumocephalus
Dizdar O., Kilickap S., Aksoy S., Cizginer S., Erman M.
JOURNAL OF NEURO-ONCOLOGY
, cilt.77, sa.1, ss.107-108, 2006 (SCI-Expanded, Scopus)
2006
200686. Lithium-associated hypothyroidism and thyroid papillary carcinoma: A case report
Aksoy S., Kilickap S., Erman M.
SOUTHERN MEDICAL JOURNAL
, cilt.99, sa.3, ss.279-281, 2006 (SCI-Expanded, Scopus)
2006
200687. Metastatic granular cell tumor: A case report and review of the literature
Aksoy S., Abali H., Kilickap S., HARPUTLUOĞLU H., Erman M.
ACTA ONCOLOGICA
, cilt.45, sa.1, ss.91-94, 2006 (SCI-Expanded, Scopus)
2006
200688. Nonconvulsive status epilepticus due to ifosfamide
Kilickap S., ÇAKAR M., Onal I., Tufan A., Akoglu H., Aksoy S., et al.
ANNALS OF PHARMACOTHERAPY
, cilt.40, sa.2, ss.332-335, 2006 (SCI-Expanded, Scopus)
2005
200589. Ovarian carcinoma in two patients with chronic liver disease
Isildak M., SAİN GÜVEN G., Kekilli M., Beyazit Y., ERMAN M.
WORLD JOURNAL OF GASTROENTEROLOGY
, cilt.11, sa.28, ss.4445-4446, 2005 (SCI-Expanded, Scopus)
2005
200590. Multivariate analysis of factors predictive of brain metastases in localised non-small call lung carcinoma
Kilickap S., Aksoy S., Erman M.
LUNG CANCER
, cilt.49, sa.1, ss.129, 2005 (SCI-Expanded, Scopus)
2005
200591. Fludarabine phosphate may be useful in the treatment of graft-versus-host disease
Aksoy S., Abali H., Kilickap S., DİNÇER M., Erman M.
MEDICAL HYPOTHESES
, cilt.64, sa.6, ss.1150-1152, 2005 (SCI-Expanded, Scopus)
2004
200492. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?
Erman M., Abali H., ORAN B., Haznedaroglu I., Canpinar H., KİRAZLI Ş., et al.
ANNALS OF ONCOLOGY
, cilt.15, sa.11, ss.1622-1626, 2004 (SCI-Expanded, Scopus)
2004
200493. Analysis of menstrual, reproductive, and life-style factors for breast cancer risk in Turkish women - A case-control study
ORAN B., Celik I., Erman M., BALTALI E., ZENGİN N., Demirkazik F., et al.
MEDICAL ONCOLOGY
, cilt.21, sa.1, ss.31-39, 2004 (SCI-Expanded, Scopus)
2003
200394. Coincidental detection of T-cell rich B cell lymphoma in the para-aortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer: A case report
Abali H., Eren O. Ö., Erman M., Uner A., Kose F., GÜLER N.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
, cilt.13, sa.5, ss.687-689, 2003 (SCI-Expanded, Scopus)
2003
200395. Concomitant Mycobacterium tuberculosis and Aspergillus niger infection in a patient with acute myeloid leukemia
AKSOY D., TURKER A., ALTUNDAG M. K., ABALI H., DURUSU M., ERMAN M., et al.
CHEMOTHERAPY
, cilt.49, sa.5, ss.264-266, 2003 (SCI-Expanded, Scopus)
1998
199896. Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis
ARIKAN S., AKOVA M., HAYRAN M., OZDEMIR O., ERMAN M., GUR D., et al.
CLINICAL INFECTIOUS DISEASES
, cilt.26, sa.4, ss.903-908, 1998 (SCI-Expanded, Scopus)
1997
199797. A randomized multicenter comparative study of cefepime and ceftazidime in combination with amikacin in the treatment of patients with fever and neutropenia
ERMAN M., Akan H., KORTEN V., Ferhanoǧlu B., UZUN Ö., ÜNAL S., et al.
Clinical Infectious Diseases
, cilt.25, sa.2, ss.463, 1997 (SCI-Expanded, Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2024
20241. Efficacy of systemic treatments in patients with metastatic lung invasive mucinous adenocarcinoma
Demir T., Araz M., Hendem E., Kocak M. Z., Erman M., Bas O., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)
2020
20202. Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience
Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., et al.
Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38, (Özet Bildiri)
2018
20183. BİR ÜNİVERSİTENİN SİGARA BIRAKMA ÜNİTESİNE BAŞVURANLARIN ÖZELLİKLERİ VE SİGARA BIRAKMA OLASILIKLARI
ŞENGELEN M., ÇELİK İ., ERMAN M., Tezcan S., YÜCE D., Kamışlı S., et al.
2. ULUSLARARASI 20. ULUSAL HALK SAĞLIĞI KONGRESİ, Antalya, Türkiye, 13 - 17 Kasım 2018, (Özet Bildiri)
2018
20184. TRANSCULTURAL ADAPTATION OF EORTC-QLQ-CR29 SCALE INTO TURKISH, AND ASSESSMENT OF VALIDITY ANDRELIABILITY IN TURKISH PATIENTS WITH COLORECTAL CANCER
HAYRAN K. M., YÜCE D., KILIÇKAP S., houssein b., ERMAN M., DİZDAR Ö., et al.
ISPOR Asia Pacific 2018, Tokyo, Japonya, 8 - 11 Kasım 2018, cilt.1, ss.11, (Tam Metin Bildiri)
2018
20185. EFFECTS OF CANCER TYPES ON LOCAL AND OUT-OF-CITY ADMISSIONS FOR MEDICAL CARE
HAYRAN K. M., YÜCE D., KILIÇKAP S., DİZDAR Ö., houssein b., ERMAN M., et al.
ISPOR Asia Pacific 2018, Tokyo, Japonya, 8 - 11 Kasım 2018, (Özet Bildiri)
2018
20186. İki olgu nedeniyle Nivolimumaba bağlı akciğer toksisitesi
BABAOĞLU E., SARINÇ ULAŞLI S., KÖKSAL D., ERMAN M., BARIŞTA İ.
Ulusal Akciğer Sağlığı Kongresi, Türkiye, 14 - 18 Mart 2018, (Özet Bildiri)
2017
20177. Brain Tissue Follow-up Using Dynamic Susceptibility Contrast-Enhanced and Dynamic Contrast-Enhanced Perfusion Magnetic Resonance Imaging on Lesions Categorized by Apparent Diffusion Coefficient Values in Glioblastoma
OMAY B., ARDALI S., MUT AŞKUN M., KILIÇKAP S., ERMAN M., KARLI OĞUZ H. K.
Radiology Society of North America, 26 Kasım - 01 Aralık 2017, (Özet Bildiri)
2017
20178. Efficiency of a psychoeducational Intervention for smoking cessation in a specialized cessation clinic
YÜCE D., KAMIŞLI S., KÜÇÜKÇOBAN ş., HAYRAN K. M., KILIÇKAP S., ÇELİK İ., et al.
2017 World Congress of Psycho-Oncology, 14 - 18 Ağustos 2017, (Özet Bildiri)
2017
20179. Metastatik kastrasyona dirençli prostat kanser hastalarında kabazitakselin güvenlik verileri: Kabazitaksel Türkiye insani amaçlı ilaca erişim programı sonuçları
BAVBEK S., BAŞARAN M., ÖZEN A. H., ERMAN M., ÖZDOĞAN M., ÖZGÜROĞLU M., et al.
22. ULUSAL KANSER KONGRESİ, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri)
2017
201710. Smoker relatives of inpatients: A reasonable but heterogeneous target population for smoking cessation program
AKTAŞ B. Y., HOUSSEİN b., YÜCE D., DİZDAR Ö., KILIÇKAP S., ERMAN M., et al.
7th ECTOH Conference on Tobacco or Health, Porto, Portekiz, 22 - 25 Mart 2017, (Özet Bildiri)
2016
201611. Tirozin Kinaz İnhibitörü Kaynaklı Tiroid Fonksiyon Bozukluğu
TECEN K., ÖZDEMİR N., KARA E., EKİNCİOĞLU A., DEMİRKAN S. K., ERMAN M., et al.
18. ULUSAL İÇ HASTALIKLARI KONGRESİ, Türkiye, 12 - 16 Ekim 2016, (Özet Bildiri)
2016
201612. Using geographical information systems to describe quality of life as a function of distance in cancer patients
HAYRAN K. M., ERMAN M., KILIÇKAP S., DİZDAR Ö., YÜCE D., HÜSEYİN B., et al.
ISPOR Asia Pacific Meeting 2016, 3 - 06 Eylül 2016, cilt.19, ss.892, (Özet Bildiri)
2015
201513. Factors that affect the suitability of cancer patients for clinical drug trials in Turkey: Final analysis of a multicenter study.
Erman M., Kilickap S., Ekinci A. S., Koca S., Ata A., Besen A., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2014
201414. Temporal changes in the survival of metastatic renal cell cancer patients and the impact of targeted agents: Single center experience
Erman M., Arik Z., Kilickap S., Bilen C. Y., Yazici S., Akdogan B., et al.
Genitourinary Cancers Symposium, San-Francisco, Kostarika, 30 Ocak - 01 Şubat 2014, cilt.32, (Özet Bildiri)
2006
200615. Anti TNF treatment may induce EBV reactivation in RA patients A clue for increased risk of lymphoma
TOKGÖZOĞLU S. L., ERTENLİ A. İ., KALYONCU U., ALP A., KARADAĞ Ö., ERMAN M., et al.
Annual European Congress of Rheumatology (EULAR 2006), 21 - 24 Haziran 2006, (Tam Metin Bildiri)
2006
200616. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma
Kilickap S., Yavuz B., Aksoy S., Sahiner L., Harputluoglu H., Dincer M., et al.
30th Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.202, (Özet Bildiri)
1996
199617. An open study of clarithromycin in the treatment of pneumonia due to Streptococcus pneumoniae
HAYRAN M., Erman M., GUR D., Akova M., Unal S.
3rd International Conference on the Macrolides, Azalides, and Streptogramins, Lisbon, Portekiz, 24 - 26 Ocak 1996, cilt.21, ss.429-431, (Tam Metin Bildiri)
Kitaplar
2018
20181. Kastrasyona dirençli prostat kanseri tedavisi
ERMAN M., ARIK Z.
Üroonkoloji Kitabı, , Editör, Nobel, 2018
Desteklenen Projeler
2023 - 2024
2023 - 2024Nivolumab Tedavisi Uygulanan İleri Evre ve Metastatik Küçük Hücreli Dışı Akciğer Kanseri Hastalarının Klinik Radyolojik Özelliklerinin ve LAG3 ve CD155 Ekspresyonlarının Tedavi Yanıtı ve Sağkalım Üzerine Etkilerinin Değerlendirilmesi
Yükseköğretim Kurumları Destekli Proje , BAP Diğer
ERMAN M. (Yürütücü), ÖNDER S. Ç., APAYDIN ROLLAS A. E.
2020 - 2023
2020 - 2023
Tedavide tirozin kinaz inhibitörü kullanılan metastatik renal hücreli kanserli hastaların prognozunda patolojik örneklerde adipokin ve kemokin etkisinin incelenmesi
Yükseköğretim Kurumları Destekli Proje , BAP Araştırma Projesi
ERMAN M. (Yürütücü), AKTEPE O. H., KÖSEMEHMETOĞLU K., GÜNDOĞDU F.
2011 - 2018
2011 - 2018Görsel Eğitsel Programla Kemoterapi Alan Hastalara Verilen Eğitimin Etkinliğinin Değerlendirilmesi
Yükseköğretim Kurumları Destekli Proje , BAP Araştırma Projesi
ERMAN M. (Yürütücü)